Key Highlights

  • Schrödinger (NASDAQ:SDGR) reported third-quarter 2026 total revenues of USD 64.5 million, up from USD 54.3 million, with drug discovery Revenue of USD 24.2 million against USD 13.0 million.
  • The net loss widened to USD 37.7 million, or USD 0.50 per share, from USD 32.8 million, or USD 0.45, even though the loss from operations narrowed to USD 26.1 million from USD 45.9 million.
  • A USD 14.8 million negative change in Fair Value of Equity investments, compared with a USD 9.7 million gain a year earlier, drove the wider net loss.
  • Cash and cash equivalents were USD 247.0 million and marketable securities were USD 119.4 million at September 30, 2026, versus USD 230.5 million and USD 164.9 million at year end.

Drug Discovery Revenue Nearly Doubles While Software Edges Up

Schrödinger (NASDAQ:SDGR) filed its Quarterly Report on November 4, 2026, for the three months ended September 30. Drug discovery revenue of USD 24.2 million was up about 86% from USD 13.0 million (calculated), and the filing notes USD 1.2 million of it came from a related party. Software products and services revenue rose to USD 38.2 million from USD 35.9 million. Contribution revenue fell to USD 2.2 million from USD 5.4 million. Total revenues rose to USD 64.5 million, and Gross Profit increased to USD 38.3 million from USD 28.0 million.

Lower Research Spending Narrows the Operating Loss

Schrödinger sells physics-based software for molecular modeling and runs its own drug discovery programs and collaborations. Research and Development spending fell to USD 34.1 million from USD 42.8 million, and general and administrative expense dipped to USD 20.3 million from USD 21.7 million, while sales and Marketing edged up to USD 10.0 million. Total operating expenses were USD 64.4 million against USD 74.0 million, which trimmed the loss from operations by about 43% (calculated). The Reversal came below the operating line. The change in fair value of equity investments swung to a USD 14.8 million loss, which pushed the pretax loss to USD 37.6 million. Nine-month net loss narrowed to USD 91.8 million, or USD 1.23 per share, from USD 135.8 million, or USD 1.85, though nine-month software revenue fell to USD 106.3 million from USD 116.9 million.

Liquidity, Collaboration Milestones and Valuation Swings

Combined cash and marketable securities were about USD 366.4 million (calculated), compared with USD 395.5 million at the end of 2025. The Novartis collaboration signed in November 2024 carries a USD 150.0 million upfront payment and eligibility for up to USD 1.424 billion in milestone payments, so revenue can vary with milestone timing. Equity Investment marks add Earnings Volatility unrelated to operations. A further risk is that Schrödinger (NASDAQ:SDGR) may not meet its own guidance; the material reviewed contains no guidance figures or consensus comparison, and no share price reaction is stated. The company also listed cost reductions from a restructuring among its forward-looking topics, but the portion reviewed gives no details.

Where Things Stand

Because a USD 14.8 million equity investment loss outweighed a USD 19.8 million improvement in operating loss. At Schrödinger (NASDAQ:SDGR), drug discovery revenue grew about 86% (calculated) and research spending fell, yet net loss per share worsened to USD 0.50 from USD 0.45. The equity mark is non-operating and can reverse. Software revenue is growing in the quarter but is lower over nine months. Next markers are milestone payments under collaborations, the software revenue trend, any further expense reductions and the direction of the equity investment valuations.